To further prove the relevance of RHAMM expression in NSCLC to clinical pathological stages, we used the Director's Challenge cohort with lung adenocarcinomas from caArray of National Cancer Institute for validation [29]. This evidence concerns the gene HMMR and lung adenocarcinoma.